Metabolic disease continues to be a formidable challenge because of its complexity. Early
identification is difficult prior to overt damage and it is difficult to manage because of
the complex intertwining of co-morbidities.1, 2 There is a challenge of bringing new drugs
to market, often attributed to a deficit between pre-clinical knowledge and clinical
efficacy, which illustrates the need for better translatability of preclinical research to the
population of patients likely to benefit. Metabolomics is an approach that can help to
address these issues.